Intelligence · Clinical pipeline
Phase III Pipeline Programs
Late-stage pivotal and registrational clinical programs nearing regulatory submission.
Quick answer
NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.
Top sponsors
- Takeda 393 programs
- United Therapeutics Europe 199 programs
- Anaxis Pharma 198 programs
- Chinese Academy of 189 programs
- Teva Pharma 148 programs
- Novartis India 145 programs
- BRIGHT MINDS BIOSCIENCES 139 programs
- PARItec 139 programs
- HOFFMANN-LA ROCHE 134 programs
- Regeneron UK 129 programs
- AstraZeneca 120 programs
- First People's Hospital 117 programs
Pipeline programs
-
D24-P009
Pari Pharma GmbH
Aneurysmal Subarachnoid Hemorrhage
1 trial -
D3 (Penta 21)
Fondazione Telethon ETS
HIV-infected
1 trial -
D3250C00101
AstraZeneca AB
Eosinophilic Asthma
1 trial -
D3252C00002
AstraZeneca AB
Severe CRSwNP patients with asthma.
1 trial -
D3253C00001
AstraZeneca AB
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
1 trial -
D3254C00001
AstraZeneca AB
Hypereosinophilic Syndrome (HES)
1 trial -
D346BC00001
AstraZeneca AB
Cutaneous Lupus Erythematosus
1 trial -
D3612L00005
AstraZeneca
HR+ / HER2- advanced breast cancer
1 trial -
D3614C00001
AstraZeneca AB
Triple-negative Breast Cancer
1 trial -
D3615C00001
AstraZeneca AB
Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
1 trial -
D361BC00001
AstraZeneca AB
Metastatic Hormone-sensitive Prostate Cancer Characterised by PTEN deficiency
1 trial -
D361EC00001
AstraZeneca AB
Metastatic Castration Resistant Prostate Cancer (mCRPC)
1 trial -
D4191C00140
AstraZeneca AB
Advanced Biliary Tract Cancers
1 trial -
D419CC00002
AstraZeneca AB
Advanced hepatocellular carcinoma (HCC)
1 trial -
D419JC00001(POTOMAC)
AstraZeneca AB
Non-muscle invasive bladder cancer
1 trial -
D4325C00010
AstraZeneca AB
Chronic Kidney Disease and High Proteinuria
1 trial -
D5086C00001
AstraZeneca AB
MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma
1 trial -
D5087C00001
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
D5160C00048
AstraZeneca AB
Histologically documented non-small cell lung cancer of predominantly non-squamous pathology who present with locally advanced, unresectable (Stage III) disease, whose tumor tissue has EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, either alone or in combination with other EGFR mutations, as detected by cobas® EGFR Mutation Test v2 (Roche Diagnostics) and whose disease has not progressed following definitive platinum-based chemoradiation.
1 trial -
D5162C00042
AstraZeneca AB
Non-Small Cell Lung Cancer
1 trial -
D5169C00001 FLAURA2
AstraZeneca AB
Patients with locally-advanced or metastatic EGFRm (Ex19del and/or L858R) Non-Small Cell Lung Cancer.
1 trial -
D516AC00001
AstraZeneca AB
Patients with histologically or cytologically documented non-squamous NSCLC with completely resectable (Stage II - IIIB N2) disease
1 trial -
D516FC00001(ADAURA2)
AstraZeneca AB
Stage IA2-IA3 non-small cell lung carcinoma, with EGFR mutation type (Ex19del, L858R), following complete tumour resection.
1 trial -
D516KC00001
AstraZeneca AB
Non squamous non-small cell lung cancer (NSCLC)
1 trial -
D516NC00001
AstraZeneca AB
Epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non squamous non-small cell lung cancer
1 trial -
D5180C00016
AstraZeneca AB
Severe Uncontrolled Asthma Asthma (an illness that causes breathing difficulty) that is not fully controlled, so that asthma attacks are still occurring despite the use of other available treatments
1 trial -
D5241C00006
AstraZeneca AB
Chronic obstructive pulmonary disease (COPD)
1 trial -
D533BC00001
AstraZeneca AB
Advanced or Metastatic Non-Small Cell Lung Cancer
1 trial -
D5982C00006
AstraZeneca AB
Inadequately Controlled Asthma
1 trial -
D5982C00007
AstraZeneca AB
Severe and inadequately controlled asthma
1 trial -
D5982C00008
AstraZeneca AB
Severe and inadequately controlled asthma
1 trial -
D5985C00002
AstraZeneca AB
Moderate to Severe Chronic Obstructive Pulmonary Disease(COPD)
1 trial -
D5989C00001 THARROS
AstraZeneca AB
Chronic Obstructive Pulmonary Disease (COPD)
1 trial -
D6185C00001
AstraZeneca AB
Patients with non-small cell lung cancer (NSCLC).
1 trial -
D6402C00012
AstraZeneca
Heart Failure and Impaired Kidney Function
1 trial -
D6402C00012
AstraZeneca AB
Chronic HF and comorbid impairment of kidney function who had a recent HF event to evaluate the effect of balcinrenone/dapagliflozin versus dapagliflozin alone on HF events and cardiovascular (CV) death
1 trial -
D6900C00003
AstraZeneca AB
B7-H4-Selected Advanced/Metastatic Endometrial Cancer.
1 trial -
D6972C00002
AstraZeneca AB
Chronic kidney disease (CKD) and hypertension.
1 trial -
D6972C00003
AstraZeneca AB
Chronic kidney disease (CKD) and hypertension.
1 trial -
D6973C00001
AstraZeneca AB
Prevention of Heart failure
1 trial -
D6974C00001
AstraZeneca AB
Primary Aldosteronism defined by excess aldosterone secretion
1 trial -
D7000C00001
AstraZeneca AB
COVID-19
1 trial -
D7025C00001
AstraZeneca AB
Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma or muscle invasive gallbladder cancer GBC)
1 trial -
D7029C00001
AstraZeneca AB
Advanced Hepatocellular Carcinoma
1 trial -
D702AC00001
AstraZeneca AB
HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
1 trial -
D702BC00001
AstraZeneca AB
Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1
1 trial -
D702FC00001
AstraZeneca AB
Metastatic Non-squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1
1 trial -
D702GC00001
AstraZeneca AB
Lung Cancer
1 trial
Frequently asked questions
How many Phase III pipeline programs are in the directory?
5,427 published programs match this development stage in our ClinicalTrials.gov index.
What defines this pipeline stage?
Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.